Percutaneous pulmonary valve implantation is highlighted as a safe and effective treatment for patients with pulmonary valve insufficiency or stenotic RVOTs following congenital heart disease repair.
Answers are grounded in this paper and cite their sources.
May guide shared decisions in congenital heart disease; leaves open need for randomized durability data.
Pulmonary regurgitation (PR) is a frequent sequelae after repair of tetralogy of Fallot, pulmonary atresia, truncus arteriosus, Rastelli and Ross operation. Due to patient growth and conduit degeneration, these conduits have to be changed frequently due to regurgitation or stenosis. However, morbidity is significant in these repeated operations. To prolong conduit longevity, bare-metal stenting in the right ventricular outflow tract (RVOT) obstruction has been performed. Stenting the RVOT can reduce the right ventricular pressure and symptomatic improvement, but it causes PR with detrimental effects on the right ventricle function and risks of arrhythmia. Percutaneous pulmonary valve implantation has been shown to be a safe and effective treatment for patients with pulmonary valve insufficiency, or stenotic RVOTs.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2012) conducted a review in Pulmonary regurgitation and right ventricular outflow tract obstruction. Percutaneous pulmonary valve implantation was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: